# OnCo record egfr-l858r (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/egfr-l858r/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "egfr-l858r" ;
  schema:name "EGFR L858R"@en ;
  schema:alternateName "L858R"@en, "EGFR exon 21 L858R"@en, "exon 21 substitution"@en, "EGFR L858R mutation"@en, "p.L858R"@en ;
  schema:description "L858R is a single letter change in exon 21 of EGFR that keeps the kinase active. It is the second commonest sensitising mutation and shares every EGFR inhibitor label with the exon 19 deletion."@en ;
  schema:url <https://onco.cc/biomarkers/egfr-l858r/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7> ;
  onco:tag "biomarker", "egfr" ;
  onco:related <https://onco.cc/biomarkers/egfr-exon-19-deletion/>, <https://onco.cc/biomarkers/egfr-t790m/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/dacomitinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/drugs/cobas-egfr-mutation-test/> ;
  onco:terms <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/egfr-mutation-subtypes/> .